1 ML filgrastim-ayow 0.3 MG/ML Injection [Releuko]

RxCUI
2595957
RxNorm name
1 ML filgrastim-ayow 0.3 MG/ML Injection [Releuko]
Display name
1 ML filgrastim-ayow 0.3 MG/ML Injection [Releuko]
Full name
1 ML filgrastim-ayow 0.3 MG/ML Injection [Releuko]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:03

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761082Releukofilgrastim-ayow351(k) BiosimilarRx2026-10-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
74e1ec6e-1630-4654-895c-2bd355f939e7Releuko 300 MCG in 1 ML Injection [PSN] · 1 ML filgrastim-ayow 0.3 MG/ML Injection [Releuko] [SBD] · Releuko 0.3 MG/ML per 1 ML Injection [SY] · Releuko 300 MCG per 1 ML Injection [SY]428These highlights do not include all the information needed to use RELEUKO safely and effectively. See full prescribing information for RELEUKO. RELEUKO ® (filgrastim-ayow) injection, for subcutaneous or intravenous use. Initial U.S. Approval: 2022 RELEUKO (filgrastim-ayow) is biosimilar* to NEUPOGEN ® (filgrastim)20250424